Andrew:
I like the release. It gives a lot of the "deal basics". The manufacturing premium could guarantee a life, going forward.
Seems like a 20% share of development expenses is too heavy of a burden for TCLN? The "worldwide" part is always a disappointment, to me, unless there's a real strong indication that either (1) the royalty is super-high, or (2) the upfront allows for development of something else in the pipe.
I'm interested in what is meant by "will also assume 80% of the existing clinical trial costs". Does that mean going forward? If not, I like the deal a lot more. Little chance of that, I guess.
Seems, to me, that the deal is as strong as could be expected, but reflects the sad state of the TCLN business plan. I agree, the tickler regarding VTA is of interest, but..... it's full of ifs and maybes, and I never like to see an indication that potential partners have been narrowed down before the actual execution of a deal.
Looks like about the best deal they could have landed, IMO, given the circumstances.
Rick |
